Skip to main content
. Author manuscript; available in PMC: 2011 Aug 1.
Published in final edited form as: Cancer Res. 2011 Jan 25;71(3):747–757. doi: 10.1158/0008-5472.CAN-10-2267

Figure 5.

Figure 5

Dasatinib inhibits mutant p53-driven PDAC cell invasion. A,B H&E-stained sections and quantification of mutant p53R172H or p53R175H -driven PDAC cell invasion ± dasatinib in the organotypic matrix at 8-12 days. Columns, mean; bars, SE. **, P < 0.01